given a beverage of similar appearance, odour and taste without any of these nutrients. Both active treatment and placebos were given for 3 months.
Event-related potentials testing was performed on all subjects on two occasions, before and after the treatment period. Event-related potentials testing was conducted according to International Federation of Clinical Neurophysiology standards using a binaural auditory tone stimulus. 13 Two easily discernible tones were presented in a random order using the so-called 'odd-ball' paradigm: that is, contrasting a 'frequent' tone of pitch, 1000 Hz, in 80% of the trail with a 'rare' tone of pitch, 2000 Hz, in 20% of the trail. Recordings were obtained from the vertex and referenced to linked-earlobe electrodes, using 0.5 Hz high pass and 30 Hz low pass filters with the sweep duration set at 750 ms. The subjects were required to count the number of rare tones mingled with a series of frequent stimuli. In normal subjects an N1-P2 complex should be identified in response to the frequent tone and an N1-P2-N2-P3 complex in response to the rare tone. 13 At the same time as ERP testing was performed the subjects had an IQ test using the Chinese-Binet Intelligence scale as revised by Cunren Fan. 15 This revised version of the Binet test has been used extensively in China since it was published in 1992. The test provides an overall evaluation of development level along with a measurement of sub-areas of clinical interest, such as language, memory, concept, thinking, reasoning, visual perception and social skills. Average IQ was defined as being a score between 90 and 109.
The entire study was conducted in a double-blind fashion. Averaged ERP for each subject were used for calculation. Three cases in the IDA group (two in the treatment group and one in the placebo group) were excluded from statistical analyses because of an absence of pretreatment P300 components.
Results
The baseline data for the three sample groups are shown in Table 1 .
Haematology
Haemoglobin levels rose in the treatment IDA group such that they were no longer significantly different to those of the non-anaemic control subjects, with all treated subjects having haemoglobin levels greater than or equal to 120 g/L (meaning that all treated subjects had an increase in haemoglobin levels of more than 10 g/L over the original level). This was associated with corresponding improvements in other haematological parameters of anaemia. Hematological indices in the placebo group improved slightly, but remained statistically different to the control group (P < 0.05) (see Table 2 ).
Event-related potentials
Prior to treatment, both IDA groups had prolonged P300 latencies in comparison with the control group (P < 0.01). Although there were differences in the proportion of cases with abnormal waveforms between each IDA group and nonanaemic controls (Table 3) , this did not reach statistical significance (treatment group vs control group χ 2 = 3.09, P = 0.079; placebo group vs control group χ 2 = 2.83, P = 0.092). When the combined two IDA groups were compared with the control group the difference was of increased significance, although it was still not statistically significant (χ 2 = 3.63, P = 0.057).
The differences in proportion of abnormal waveforms within each group comparing pre-with post-treatment testing did not reach statistical significance for any one group, although there was a trend to more abnormal waveforms in the placebo group (P = 0.052), and less abnormal waveforms in the treatment group (P = 0.174). The proportion of abnormal waveforms in the non-IDA control group did not change. However, the differences in proportion of abnormal waveforms between groups during post-treatment testing were of high statistical significance. There was a decrease in the number of cases with abnormal waveforms in the active treatment group, compared with an increase in the number within the placebo group (P = 0.002). In relation to the severity of these abnormalities, the trend was towards increasing severity in the placebo IDA group compared with decreasing severity in the treatment IDA group (as illustrated in Fig. 1) . Table 4 shows the data on latencies and amplitudes for the three groups. Pre-treatment, the P3 absolute latencies of both IDA groups were significantly longer than those of nonanaemic controls (P < 0.01). Post-treatment, these differences were reduced but were still statistically significant (P = 0.05) in the case of the placebo IDA subjects compared with the non-IDA controls. However, the P3 absolute latencies were no longer significantly different between the treated IDA subjects and the non-IDA controls (P > 0.1).
There were clear reductions on N1 and P3 peak latencies in both treatment and placebo groups between the pre-and post-treatment testing, but this reduction was less in the placebo group than in the treatment group. Table 5 shows the results for IQ testing. Despite a trend towards lower scores in both IDA groups compared with non-IDA controls pre-treatment, there were no statistically significant differences. However, the treatment group was significantly higher compared with the placebo IDA group after treatment (P < 0.05).
Discussion
Iron is an essential trace element in the human body. It is well established that although mild IDA often has few obvious clinical symptoms it can adversely affect higher cerebral function, particularly in children during their vigorous and vulnerable stages of psychomotor and physical development. [16] [17] [18] [19] [20] [21] [22] The present study was undertaken to explore whether any evidence of cognitive disturbance could be found through neurophysiological assessment (such as ERP) or by psychological evaluation (such as IQ testing). Eventrelated potentials have already been used in the diagnostic assessment of various diseases other than IDA; for example, epilepsy, Down syndrome, schizophrenia, Parkinson's disease and diabetes mellitus. 12, [23] [24] [25] [26] Our data show that IDA is associated with significant changes in latency prolongation of P300 and distortion of P300 waveforms, suggesting that IDA causes cognitive disturbances in children. It was particularly noteworthy that Event-related potentials in IDA children 93 three IDA subjects had a complete absence of P300 waveforms despite their having been able to maintain an accurate count of the rare stimuli, something that was not seen in any of the non-anaemic controls. This phenomenon has been reported previously in the literature in patients with lesions of the auditory areas of the cerebrum and the neocortex, 27, 28 where it has been suggested as a sign of compromised cognitive processing. 27 The data also show some association between ERP results and IQ test scores. Previous studies have shown an inverse correlation between P300 latency and total IQ scores, such as in epileptic children with disrupted cognitive function where prolonged P300 latency is accompanied by low IQ scores, 12 and in gifted children where higher IQ scores are found together with short P300 latency. 29 Our findings are consistent with this association.
The present study showed that iron supplementation was effective in treating anaemia, although the more contentious issue is whether iron supplementation is effective in reversing any cognitive disturbances which may be present. Walter reported that iron therapy was unable to reverse cognitive disadvantages, reflected in psychological tests, even after complete correction of haematological parameters in a majority of infants with IDA. 6 However, Vega-Franco et al., looking at older children aged 6 to 11 years, found that 12 weeks of iron therapy had a favourable effect on the attention spans of IDA subjects. 19 Further, Soewondo found that the alterations in cognitive processes in children aged 3 to 6 years with IDA could be reversed with iron treatment. 20 Our data tend to support the more positive view. Treatment of IDA children in the present study was associated with a highly significant reduction in the latency of P300 (P < 0.002) such that the treated IDA group was no longer statistically significantly different to the non-IDA controls. This group also showed a significant enhancement of their IQ test scores (P < 0.05). There are a number of possible explanations for these positive outcomes. Firstly, the children in this study were school-aged rather than infants. Secondly, their iron deficiency and cognitive impairment were not severe.
These results also highlight the advantages of ERP testing as a test of cognitive function in children with IDA in comparison with IQ testing. The determination of IQ is influenced by a number of subjective elements, particularly in children, whereas auditory ERP are objective and require only minimal cooperation of the subject. They offer quantitative measurement of the extent and severity of cognitive dysfunction, 30, 31 and the present results show that this is a useful measure in mild cases of IDA such as were seen here.
In summary, the present study suggests that ERP may be a very useful tool in diagnosis of minor cognitive disturbance in school-aged children with asymptomatic IDA. Eventrelated potentials were related to IQ scores, and these results support the conclusion of other authors that ERP may be the method of choice for longitudinal assessment of pathological effects on cognitive function. 32 Used early in the process of cognitive damage in children with IDA, ERP may help in the prevention of irreversible brain damage. It is also possible to administer this test to infants with IDA in order to confirm whether there are any cognitive disturbances, given that P300 can be elicited from infants with auditory stimuli through a passive tone sequence paradigm. 33 Table 5 . The changes in IQ at different periods
